Feasibility of an Evolutionary Tumor Board for Generating Novel Personalized Therapeutic Strategies

Mark Robertson-Tessi¹, Joel S. Brown¹, Maria I. Poole², Matthew Johnson², Andriy
Marusyk³, Jill A. Gallaher¹, Kimberly A. Luddy¹, Christopher J. Whelan³, Jeffrey West¹,
Maximillian Strobl¹, Virginia Turati¹, Heiko Enderling¹, Michael J. Schell⁴, AikChoon
Tan⁵, Terry Boyle⁶, Rikesh Makanji⁷, Joaquim Farinhas⁷, Hatem Soliman⁸, Dawn
Lemanne^{9, 10}, Robert A. Gatenby⁷, Damon R. Reed¹¹, Alexander R. A. Anderson^{1,*} and
Christine H. Chung^{2,*}

9

¹Department of Integrated Mathematical Oncology, ²Department of Head and Neck-10 Endocrine Oncology, ³Department of Cancer Physiology, ⁴Department of Biostatistics 11 and Bioinformatics, ⁶Department of Pathology, ⁷Department of Radiology, ⁸Department 12 of Breast Oncology, ¹¹Department of Individualized Cancer Management; H. Lee Moffitt 13 Cancer Center and Research Institute, Tampa, Florida 14 ⁵Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, 15 Salt Lake City, UT 16 ⁹Oregon Integrative Oncology, Ashland, Oregon 17 ¹⁰Department of Medicine, University of Arizona, Tucson, Arizona 18 19 Running Title: Evolutionary Tumor Board for Novel Therapeutic Strategies 20 21 Key words: evolution, multi-disciplinary cancer care, adaptive therapy, mathematical 22 models, evolutionary therapy 23

24 *Co-Corresponding authors:

- 25 Christine H. Chung, MD
- 26 Christine.Chung@Moffitt.Org
- 27 Alexander R. A. Anderson, PhD
- 28 Alexander.Anderson@Moffitt.Org
- 29 12902 Magnolia Dr. Tampa FL, 33612
- 30

Potential Conflict of Interest: HE holds U.S. Patent 63/279,994: Bayesian Framework 31 32 to Augment Tumor Board Decision Making (provisional), U.S. Patent 62/040,579: Predicting glioma treatment response (provisional), and U.S. Patent 33 62/944,804: Methods for prostate cancer intermittent adaptive therapy (provisional). TB 34 received Research funding support from Bristol Myers Squibb and has stock ownership 35 in Ionis Pharmaceuticals. HS received honoraria from AstraZeneca, Seattle Genetics, 36 Merck, and Novartis for serving in ad hoc scientific advisory boards. DRR received 37 honoraria from Springworks and Eisai for serving in Data Safety Monitoring Committee. 38 CHC received honoraria from Sanofi, Merck, Brooklyn ImmunoTherapeutic, Fulgent, 39 and Exelixis for serving in ad hoc scientific advisory boards. All other authors declared 40 no conflict of interest. 41

42

43 **ABSTRACT**

The current paradigm of clinical trials treating patients until disease progression using 44 maximum tolerated dose does not account for the dynamic tumor-host-drug interactions 45 that result in acquired resistance. Here, we present the concept of an Evolutionary 46 Tumor Board (ETB) and report interim results from a prospective, non-interventional 47 pilot study in which novel therapeutic strategies based on evolutionary principles were 48 developed under the ETB framework. The ETB approach relies on an interdisciplinary 49 team that integrates clinical, preclinical, and theoretical knowledge and the application 50 51 of mathematical modeling to predict patient responses to different therapies, including 52 novel approaches derived from eco-evolutionary first principles. We have previously proposed several evolutionary therapies that aim to enhance the efficacy of an overall 53 treatment regimen, using existing agents for a given disease. Key among these 54 55 evolutionary therapies is the idea of "first-strike second-strike", where different agents are administered in sequence, and new strikes are applied as soon as the efficacy of 56 57 the previous strike is nearing a minimum, as opposed to waiting until progression is identified on periodic imaging. This approach requires careful analysis of longitudinal 58 patient data coupled with predictive dynamics generated by mathematical models. Here 59 we describe the ETB process and the interim results from 15 patients enrolled in the 60 feasibility trial. In addition, we describe the challenges faced as well as the solutions 61 62 that can be implemented via improved modeling approaches, better patient data collection, and a reassessment of how we understand tumor dynamics in the light of 63 64 evolutionary principles.

65

66 INTRODUCTION

Cancer is one of the major public health concerns globally, and the American Cancer Society estimates approximately 1,918,030 new cases will be diagnosed in the United States alone in 2022¹. With breakthrough advances in cancer screening, targeted therapies, and immunotherapies, overall cancer mortalities have been decreasing. However, cancer is still the second leading cause of death in the U.S., with an estimated 609,360 people expected to die from cancer in 2022. Therefore, the development of novel strategies to improve outcomes remains urgent.

74

The general paradigm of novel therapy development in currently "incurable" cancers (by 75 current standard of care) that are recurrent and/or metastatic with resistance to existing 76 treatments has been focused on molecular characterization of a tumor for targeted 77 leveraging immune checkpoint inhibition, and identifying predictive 78 therapies. biomarkers to select the most efficacious regimen. However, this approach benefits only 79 a limited number of patients with targetable genomic aberrations and tumors with 80 immune responsive phenotypes; furthermore, most of these patients exhibit transient 81 responses due to the evolution of acquired resistance over time. This limitation is, at 82 least in part, due to the lack of a comprehensive evaluation of the dynamic tumor-host-83 treatment interactions over time. Consideration of evolution under treatment selection 84 85 and subsequent changes in tumor phenotype is not a novel concept; nevertheless, strategies for using this perspective to guide systemic therapies are lacking. Too often 86 oncology strategies are static. The prevailing clinical intervention is reactionary after 87 resistance develops, and not proactive to curtail evolutionary dynamics². From the 88

89 development of the first cancer cell, natural selection favors phenotypes that increase fitness and eliminates those that do not, and this process continues through therapy^{3,4}. 90 We continue to select systemic therapies empirically based on the observable response 91 92 in the dominant population because we are often unable to account for resistant minor populations during the treatments that will eventually lead to recurrence. For patients 93 with incurable cancers, we must better understand the evolutionary dynamics that lead 94 to the emergence and predominance of therapy-resistant phenotypes, eventually 95 rendering even initially useful therapies to be ultimately ineffective. This highlights our 96 97 currently inability to incorporate evolutionary dynamics into routine clinical treatment to delay or avoid the emergence of treatment resistance. But what is a better way? 98

99

100 There are several concepts from evolution and ecology that can potentially address 101 these limitations. For example, Anthropocene species extinctions have commonly occurred when a cataclysmic perturbation (first strike) spatially fragments a large 102 103 population into small remnant populations with less genetic diversity and increased sensitivity to stochasticity that then become susceptible to what otherwise might be 104 survivable minor perturbations (second strikes, third strikes, etc.). This concept could be 105 106 leveraged to develop an "extinction treatment" regimen that aims to improve therapy by using a "first-strike" agent to generate a "cataclysmic" response, followed by a sequence 107 108 of second-strike therapy agents that might offer patients the chance of cure or complete response⁵. Furthermore, even if cure is not possible with such a sequence of strikes, 109 moving agents forward to apply them near the nadir of the previous strike has the 110

potential to foment greater overall tumor decline, and the dynamics of these diminishedtumor burdens may prolong survival.

113

114 The vast majority of currently employed strategies against cancer can be considered as first strikes. Practically speaking, first strikes are any intervention such as surgery, 115 radiation, or systemic therapy agent(s) that induce an observable response. Current first 116 strikes are evaluated by how large a response occurs (with partial or complete 117 responses seen as desirable) and how durable the response remains before 118 119 progression. In the current fixed maximum tolerated dose paradigm, the subsequent therapy is not initiated until the observation of clear disease progression after the first 120 strike. However, changing therapies upon disease progression is far too late in eco-121 122 evolutionary terms. Clinical progression simply provides delayed proof of the evolutionary and ecological recovery of cancer cell populations, often weeks or even 123 months (or years or more) after the fact. Instead, the second strike should occur when, 124 125 or even before, the cancer cell population is the smallest after the first strike. Secondstrike therapies do not need to have a proven track record for producing a large tumor 126 response like first-strike agents. Importantly, any remnant cancer populations survived 127 by the first strike may have vulnerabilities (i.e., collateral sensitivity) to second-strike 128 agents^{5,6}. 129

130

Application of extinction-based therapies poses two questions to practicing clinicians: 1) what is the appropriate timing of the second strike? and 2) what therapeutic agent(s) should be selected as the second strike? To address these fundamental questions, we

134 adapted the existing framework of the clinical tumor board that determines the best treatment options using multidisciplinary approaches and formed the Evolutionary 135 Tumor Board (ETB), broadening the traditional tumor board to include the non-clinical 136 137 disciplines such as Cancer Biology, Evolutionary Biology, Mathematical Oncology, and Bioinformatics. The ETB explicitly considers the ecological (changes in tumor burden 138 and distribution of tumors) and evolutionary (changes in the heritable characteristics of 139 the cancer cell populations) dynamics of cancer. We hypothesize that this ETB 140 approach can develop novel therapeutic strategies based on eco-evolutionary principles 141 142 that may provide longer lasting responses by using currently available drugs in new ways. 143

144

145 At the heart of evolutionarily inspired cancer therapies, cancer is seen as a complex. 146 adaptive dynamic system governed by natural selection. Evolutionary therapies model cancer cells within a tumor as an adapting and phenotypically heterogeneous 147 148 population. Central to capturing cancers' complex dynamics is patient-specific mathematical modelling (e.g. using differential equations or game theory), with its ability 149 to exploit historic response data (for model calibration) and forecast future therapy 150 151 combinations and schedules⁷. Integrating clinical experience, completed clinical trial data, retrospective patient data analysis, extensive literature review, and detailed 152 153 patient specific analysis facilitates a unique dialogue among the many involved disciplines. This results in a patient-specific decision tool, driven by predictive 154 mathematical modeling, for evaluating the possible consequences of different treatment 155 156 options. Importantly, this approach allows for detailed reassessment of care decisions

as follow-up data is received during treatment. Here, we report a description of the ETB
 workflow and framework, its feasibility, and the interim results of this pilot study.

159

160 **METHODS**

161 Study Design and Patient Selection

The prospective, non-interventional pilot study was conducted at Moffitt Cancer Center 162 under an IRB-approved protocol (MCC 20417, Feasibility of Generating Novel 163 Therapeutic Strategies based on Evolutionary Tumor Board, NCT04343365). 164 165 Institutional IRB approval was obtained in accordance with the Department of Health and Human Services Federal Policy for the Protection of Human Subjects (US Common 166 Rule) at Moffitt Cancer Center. The study was initiated after the IRB approvals and 167 168 written consents were obtained. Patients were eligible for enrollment if they were deemed to be incurable given the current standards of care, had a life expectancy over 169 3 months, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, 170 171 had a primary oncologist willing to consider the therapeutic strategies recommended by the ETB, and were willing to be followed over time and allowing clinical data collection 172 over time. This includes patients in remission but at high risk of recurrence, patients with 173 suboptimal responses to previous therapy, or patients with many potentially beneficial 174 (but not curative) options for care. There were no exclusion criteria. 175

176

The primary endpoint of the study is to determine the rate of developing evolutionarytherapy-based treatment strategies for ETB-enrolled patients without curative options. Exploratory aims include other potential results of this process: 1) To determine the rate

medRxiv preprint doi: https://doi.org/10.1101/2023.01.18.23284628; this version posted January 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

180 of implementing evolution-inspired plans by the treating physician through a chart review; 2) To assess whether evolutionary strategies recommended by the ETB 181 improve prognosis compared to a priori prognosis for patients who have exhausted 182 curative strategies through a chart review; 3) To assess the feasibility to build and refine 183 184 mathematical models to explore duration of effect and survival for ETB recommendations; 4) To assess the feasibility to analyze radiologic features of cancer 185 over time to predict duration of effect and survival for ETB recommendations; 5) To 186 assess whether changes in the circulating cell-free DNA (cfDNA) over time as a variable 187 188 is or is not informative in building mathematical models; 6) To assess whether presence of certain tumor genomic abnormalities by whole exome sequencing as a variable is or 189 is not informative in building mathematical models; and 7) To assess the feasibility of 190 generating impact hypotheses based on evolutionary and/or ecological principles to 191 improved cancer therapy. 192

193

194 **The ETB Process**

Once enrolled, a patient's disease history and treatment summary were compiled by the 195 196 oncologist and the ETB coordinator. The remaining options for care and anticipated response rates along with prognosis in terms of progression-free survival (PFS) and 197 overall survival (OS) were annotated from the literature. Collected data points include 1) 198 199 demographics, 2) social history including alcohol and tobacco use history, 3) family 200 history, 4) Eastern Cooperative Oncology Group performance status, 5) pathology, 6) any clinically relevant laboratory test and biomarker results, 7) prior therapies and 201 202 associated tumor measurements during the therapies, and 8) potentially available

203 subsequent therapies for consideration by the ETB. The tumor measurements were obtained as 1-dimensional measurements using the RECIST v1.1 criteria as a guideline 204 and 3-dimensional measurements for volumetric quantification of all measurable 205 206 lesions. In addition, for the purpose of calibrating the model, we typically utilize retrospective clinical data for the drugs under consideration for a given patient. For the 207 specific exemplar patient below, we used data from a phase II study of cetuximab and 208 nivolumab in recurrent and/or metastatic (R/M) head and neck squamous cell 209 210 carcinoma (HNSCC; NCT03370276). The detailed study population and results were previously published^{8,9}. 211

212

For each patient, at least 2 preparatory discussion meetings occurred among a subset 213 214 of the key ETB members in advance to the ETB meeting, consisting at least of primary oncologists that oversee the treatment implementation of the patient being discussed, 215 mathematical modelers, preclinical experimentalists, ecologists, radiologists, and often 216 217 other oncology disciplines and additional ad hoc members. During these discussions, the current clinical standard was discussed along with alternatives. Evolutionary 218 strategies were proposed to establish what interventions were possible and what 219 220 measurements of responses were feasible. Predictions from a patient-calibrated mathematical model and several iterations of the clinical questions in response to them 221 222 often occurred during the generation of the ETB recommended treatment plan.

223

The ETB itself was convened monthly and consisted of clinical oncologists (surgical, radiation, medical, and pediatric), radiologists, pathologists, evolutionary biologists,

mathematicians, research scientists, statisticians, data scientists, and clinical trialrelated personnel at Moffitt Cancer Center. The primary oncologist typically started by presenting their case to the multidisciplinary ETB, followed by the mathematical modelling team presenting the process and initial thoughts and plans for the patient. The interdisciplinary discussion that followed often refined and sometimes changed a therapeutic strategy, and also generated hypotheses that influenced directions for follow up preclinical work, future clinical trials, or other areas of investigation.

233

234 **RESULTS**

235 **Patient Characteristics**

A total of 15 patients were enrolled to the ETB protocol between 5/5/2020 and 4/7/2022. 236 As described below, we also used a retrospective cohort to calibrate the model. This 237 cohort consisted of a total of 26 patients with HNSCC and were obtained from the 238 phase II clinical trial of cetuximab and nivolumab^{8,9}. The patient characteristics for the 239 ETB and retrospective patients are summarized in **Table 1**. The prior line of therapy is 240 defined as the number of treatment regimens that the patient received from the time of 241 recurrent and/or metastatic disease diagnosis. Most patients were heavily treated 242 243 before enrolling to the trial, but 14 of 15 (93%) patients had good performance status with ECOG PS 0-1. 244

245

246 Development of Therapeutic Strategies based on Mathematical Modeling

The overall ETB workflow is summarized in **Figure 1A**. Each individual patient's history was collected based on the protocol requirement and summarized. Examples of the prior treatment history and data collection along with available treatment options and their estimated outcome are shown in **Supplemental Table 1** and **Supplemental Table 2.** The collected data were graphed to visualize an accurate timeline of disease burden based on the radiographical imaging studies, drug dosing, and all sequences of previous treatments (**Figure 1B**). If imaging data informed tumor burden, then the volume dynamics, appearance, and disappearance of each lesion were also included. Aggregating this information into a standardized visual treatment and response chart has proved to be an invaluable tool for ETB discussion.

257

The available clinical data points were integrated to calibrate mathematical models that 258 explore treatment options using a system of ordinary differential equations (ODEs). The 259 equations have sufficient complexity to capture the key disease dynamics observed in 260 261 patients and remain simple enough to avoid overfitting (Figure 1C). Data available for each individual patient tend to be sparse in terms of the number of time points, and thus 262 unsuitable for fitting models with numerous parameters¹⁰. In our primary model, termed 263 264 the GDRS model, we focus on four aspects of tumor dynamics: tumor Growth, tumor Death, evolution of drug Resistance, and drug re-Sensitization. The model is an 265 extension of a tumor-growth inhibition model¹¹⁻¹⁴ and consists of n+m differential 266 equations, where n is the number of distinct lesions, and m the number of drugs that are 267 administered. We let T_i be the volume of lesion i=1,...n; and D_i be the dose (as a 268 269 function of time) of drug $j=1,\ldots,m$. The efficacy of each drug over time (E_i) is distinct for 270 each drug, and changes to reflect the evolution of resistance or subsequent resensitization. In the following equations, T_i , D_i and E_i are time-dependent: 271

$$\dot{T}_{i} = \begin{pmatrix} Freatment response \\ Growth \\ \tilde{\gamma}_{i} \\ - \\ \sum_{j} \delta_{j} E_{j} D_{j} \end{pmatrix} T_{i}$$
$$\dot{E}_{j} = \begin{pmatrix} Frestitization \\ S_{j}(1 - E_{j})(1 - D_{j}) \\ - \\ F_{j} D_{j} \\ - \\ F_{j} D_{j} \end{pmatrix} E_{j}$$
$$D_{j} = D_{j}(t)$$

In this eco-evolutionary model, T_i models the ecological dynamics, E_j the evolutionary dynamics, and D_j the choices of the physician and patient. The model is further described in **Supplemental File 1**.

275

276 Model Calibration using ETB Patient Specific Data

277 To apply the model to an ETB patient's data, we made the following assumptions. First, 278 we assumed that all the lesions within a patient shared the same growth parameter (γ_i) unless there were significant indications from the data suggesting that a particular lesion 279 should have its own individualized fit. Thus, tumors within a patient only differed in 280 281 terms of their date of first appearance and initial size. When possible, growth rates were calculated from a pair of consecutive increasing volumetric measurements for a lesion. 282 283 These pairs of points were picked with the following prioritization scheme: 1) two 284 measurements for the primary lesion prior to initial therapy; 2) two measurements for any metastatic lesion while off therapy; 3) maximal growth rate found within all 285 increasing sequential measured volumetric pairs regardless of therapy status. In cases 286 where multiple pairs of points satisfied the same level from the prioritization scheme, the 287 maximal growth rate was used as the baseline. The growth rate, γ , thus derived is set to 288

be the exponential growth parameter for the patient as a whole, for all lesions. An exception arises if one or more lesions are clearly significantly different in its growth rates, in which case the outlier lesion is given its own growth rate y_i .

292

An additional factor can affect the growth rates, namely the appearance of new lesions 293 294 relative to the dates of patient scans. When a new lesion is detected, the volume is noted. Following that, the previous scan of that same area is rechecked for any prior 295 evidence of that lesion. This is a relevant check as the threshold for identifying a lesion 296 de novo is larger than identifying it post hoc, when the location is now known from later 297 scans. In either case, imaging has a lower limit of measurable size determined by 298 contrast, voxel size, etc. When tracing a new lesion back through previous scans, 299 300 eventually a scan is reached where there is no evidence of that lesion. For the model, we set its initial size in accordance with the minimal detection size of the instrument. 301 Thus, this may be an over-estimate and consequently may underestimate the tumor's 302 303 growth rate when calculated from the next scan, where the lesion was identified and measured. In some cases, this underestimate may still be higher than the growth rates 304 measured from other lesions, in which case the new lesion may receive its own higher 305 growth rate for fitting purposes. This approach of tracking individual lesions backwards 306 in time is a novel aspect of the ETB, allowing for the extraction of additional data 307 308 regarding the lesion dynamics that would otherwise not be available.

309

To fully fit the drug-induced death and resistance parameters, at least two volumetric measurements while on the same therapy are needed. In this case, the starting tumor

312 size (calculated from the pre-treatment scan), the growth rate, and the two on-treatment time points are sufficient to fit the 'U-shaped' ecological dynamics of the tumors. The 313 model then reflects initial drug efficacy (drug-induced death rate, δ) followed by 314 315 increasing drug resistance. In cases where there is only one on-treatment measurement, drug-induced death rate and rate of increasing drug resistance, r, cannot 316 both be estimated. In such cases, we specify a functional form that generates pairs of 317 parameters that fit the single on-treatment data point (Supplemental File 1). This 318 function defines a set of parameter pairs all of which fit the patient data points. In 319 320 principle, this set is wide-ranging, although biologically realistic bounds can be placed on δ and r, particularly using historical data from independent cohorts. The predictions 321 arising from the possible pairs of δ and r can vary greatly. Thus, constraining the set of 322 plausible pairs is of high value for predicting the future course of the patient's disease. 323

324

325 Model Calibration using Historical Data

326 A key aspect of the ETB process is the use of retrospective cohort data to constrain the predictions generated for the specific ETB patient. As such, we evaluated a 327 retrospective cohort of patients with recurrent and/or metastatic HNSCC (Tables 1 and 328 2). For these 26 retrospective patients, we applied the ETB analysis approach to their 329 available historical data. Imaging scans were retrieved and remeasured to both 330 331 generate volumetric measures of each lesion and look for non-target lesions that may not have been considered during typical RECIST follow-up analysis at the time of their 332 care. These data were then modeled using the above procedures to find parameter 333 334 ranges for each patient that matched their data. Specifically, ranges of growth rates for

335 lesions (y), their response to any applied therapies (δ), and their rate of becoming resistant to such therapies (r) were determined. These ranges give a starting point for 336 predicting the outcomes of the ETB patient, putting expected bounds on their growth 337 rate and response to treatments, wherever the ETB patient's data itself does not offer a 338 fit. In our exemplar patient that we describe below, we used the retrospective cohort of 339 patients receiving combination cetuximab and nivolumab to predict the widest range of 340 response to these agents expected in the ETB patient. The patient's own lesion 341 dynamics then further refines the predictions within that retrospective range of 342 343 possibilities.

344

345 Evaluation of Primary Endpoint of the Pilot Study

In 15 patients enrolled to date, 11 patients (73%) met the primary endpoint (Table 3). In 346 cases where the end point was not met, the reasons are: 1) the patient was deceased 347 before the date of the first ETB presentation, 2) insufficient historical data/analysis at the 348 349 time of ETB to predict response to additional therapy options, 3) the patient was taken off the study at physician's discretion before the ETB presentation, and 4) the patient did 350 351 not have measurable lesions delaying the presentation at ETB. In the 11 cases with recommendations, subsequent systematic chart reviews were conducted to determine if 352 the treating physician altered the patient's treatment plan based on the evolutionary 353 354 therapies recommended by the ETB. The physician and patient followed the 355 recommendation of the model in all 11 cases. All patients were longitudinally followed on the protocol for continued chart review to evaluate, after sufficient follow up, whether 356

the patient had an improved outcome compared to the *a priori* prognosis for similar patients under standard of care.

359

360 The ETB has developed a framework to evaluate novel therapeutic strategies for individual patients, including tools for temporal visualization of the treatment and 361 responses throughout the patient's cancer journey, and application of the GDRS model 362 to volumetric and other biomarker data. These tools are critical in facilitating treatment 363 decisions for each individual patient in an efficient and consistent manner. Due to the 364 often-sparse nature of clinical data, and need to constantly refine treatment decisions, 365 we developed the following decision support workflow for fitting, prediction, and analysis 366 using the ETB framework (Figure 2A). 367

368

369 Evaluation of HNSCC based on the ETB recommendation

To determine the initial feasibility of the ETB based approach, we focused on the 370 371 evaluation of HNSCC because of the immediate availability of the retrospective cohort through a recently completed clinical trial. Parallel efforts for each enrolled patient in 372 other disease sites to develop a similar model is ongoing and will be reported 373 separately. For HNSCC, we enrolled a man in his 60's with an initial diagnosis of 374 HNSCC (subject ID: ETB-003) with base of tongue primary site and cervical lymph node 375 376 metastasis based on imaging studies. The patient pursued non-standard of care alternative therapy and had local disease progression (Supplemental Table 1). The 377 repeat biopsy of cervical lymph node at the time of disease progression was p16-378 379 positive squamous cell carcinoma. The patient started palliative chemotherapy with

cisplatin, 5-fluorouracil, and cetuximab. Unfortunately, the regimen was discontinued because of toxicity after one cycle. Pembrolizumab was started, and chemotherapy was added due to disease progression on the pembrolizumab monotherapy. Again, the treatment was discontinued due to toxicities. The patient completed the concurrent carboplatin, paclitaxel, and radiation for durable locoregional control. The patient developed disease progression locally and distantly with lung metastasis and was treated with cetuximab and nivolumab.

387

For this patient with metastatic relapse, we analyzed the potential outcomes that might 388 arise with the application of first-strike second-strike therapy, also known as extinction 389 therapy (Figure 2B and Figure 2C). Upon relapse, the patient was put on the 390 combination of cetuximab and nivolumab (the first strike), which we label F1 here. The 391 goal of our analysis was to determine when the patient might fail this combination and 392 therefore intervene at the appropriate time with a second strike. In this case, there were 393 394 two chemotherapy options available as second strikes: carboplatin plus paclitaxel (S1) and cisplatin plus 5-fluorouracil (S2). Ideally, the first strike will be applied until efficacy 395 wanes and the nadir of tumor burden is near, at which point the switch to the second 396 strike would occur. In our analysis of this patient, we used retrospective cohort data, the 397 patient's previous imaging data, and the temporal follow-up data to determine 1) when 398 399 the nadir of F1 may occur, and 2) which of the second strikes to switch to.

400

401 Initial analysis and model fits

402 Figure 2B shows the initial analysis of the patient that was produced after enrollment. The dynamics of their lesions pre-ETB are shown to the left of the solid vertical line, 403 which represents the time at which the patient was first analyzed by the ETB. Some of 404 the early historical data was not available since the patient was treated at another 405 institution prior to being seen at Moffitt Cancer Center. Volumetric measurements for all 406 available scans were performed retrospectively for each detectable lesion and are 407 shown as dots on the plot. The horizontal time axis is scaled relative to the first 408 409 available scan.

410

The patient was administered several different therapies to address the primary 411 412 disease: combination regimens of chemotherapies, targeted therapy, immunotherapy, and radiotherapy, with the latter causing regression of the primary disease around day 413 760. A follow-up scan on day 878 showed no evidence of disease; however, on day 414 415 1026 there was evidence of lung and lymph node metastases. These were measured volumetrically. Knowing their positions in the lungs, the previous scan with no evidence 416 of disease (NED) at day 878 was reexamined to see if very small lesions were indeed 417 detectable, but they remained NED. Therefore, we consider that these lesions are 418 smaller than the detection threshold of the instrument, and they are marked with 'x' 419 markers on Figure 2B. Shortly before enrolling on the ETB, the patient began their first-420 strike therapy (F1) for the metastatic disease. 421

422

423 In accordance with the methods, we fit the model to the available data. The growth rate ranges were primarily fit from the metastatic disease dynamics, since there were two 424 measurements prior to starting therapy F1, and an additional upper limit from the NED 425 426 scan on day 878. Using these ranges of growth rate, we fit efficacy and resistance 427 parameters for the dynamics of the primary disease (of which a representative fit for the largest primary lesion is shown in **Figure 2B** in dark blue). A confounding factor is that 428 the drugs were primarily given in combination, and furthermore the imaging data is 429 sparse compared to the multiple changes of agents. However, some constraints on the 430 431 drug behaviors can be gained from these fits.

432

We also leveraged our retrospective data for the first-strike therapy from patients having 433 received the same F1 combination of cetuximab and nivolumab, from the clinical trial 434 described above. By fitting to the dynamics of the patients in that cohort, we determined 435 ranges of efficacy for F1 (Table 2). Application of this range to the current patient (using 436 437 the intrinsic range of growth rates and resistance rates found from their own lesion dynamics) produced the predictive cone shown in light blue (the widest cone). Naturally, 438 since some retrospective patients progressed rapidly and others had significant 439 responses, the cone encompasses a wide range of possible responses for the current 440 patient. Taking the average retrospective behavior and applying it to the current patient 441 442 produces the darker shaded region.

443

444 At this stage of the analysis and patient decision-making process, we are primarily 445 interested in knowing when the efficacy of F1 will be significantly diminished, and

446 therefore the nadir of tumor volume will be approached. This will be the time to switch to a second strike. The time-to-nadir (TTN) for the retrospective cohort parameter ranges 447 applied broadly to this patient ranges from 0 months (i.e., the efficacy of F1 is low 448 enough that the lesions are already growing through it) to 7.3 months. To refine the 449 patient-specific prediction of the nadir, we leverage model fits derived from the earlier 450 lesion dynamics, and restrict the fits generated by the retrospective cohort parameter 451 ranges to those that match the current patient's fits. After this constraint, the model 452 predicts that the current patient is likely to do significantly better than the average 453 response of the retrospective cohort. The likely TTN range is now between 4.2 months 454 and 6.9 months. Since the next scan is anticipated to be within two months of starting 455 the therapy, the model strongly suggests that switching therapies should wait until 456 457 follow-up imaging is obtained.

458

459 **First follow-up analysis**

460 Upon imaging and performing volumetric measurements of the lesions, we reanalyze the patient dynamics. Figure 2C shows the results after the first follow-up scan for the 461 462 patient at day 1119. The largest lesion has declined significantly under the first strike, F1. This decline was in line with the "Patient fit" prediction cone of Figure 2B, 463 suggesting that the growth rates and treatment dynamics determined from earlier 464 465 timepoints remained consistent for this lesion over time. The updated prediction cone for F1 is narrower after follow-up analysis using the additional data point. The TTN now 466 ranges from 1.5 to 3.5 months (from the time of follow-up, not the start of F1). The 467 468 model again suggests that the first strike is most likely to remain efficacious until the

next imaging cycle, with only a small fraction of simulations suggesting that the nadir will
be reached prior to that time.

471

472 At the same time, we examine what the effect of switching to a second strike would be at this time, since we do not want to wait until the nadir is reached to switch. In the 473 insets of Figure 2C, we show the predicted range of effect for switching from the F1 to 474 either second-strike S1 (inset A) or S2 (inset B). In both cases, the range of efficacy for 475 the strike is determined by both retrospective cohort responses and the current patient's 476 477 response, since they were previously administered these agents during primary tumor treatment. S1 was administered at the end of the primary disease treatment, and 478 therefore the estimates are better than for S2, which was only administered in 479 combination with other agents, and therefore has confounding factors in the primary fits. 480 However, in both cases, the model suggests that compared to staying with the first 481 strike, the second strikes appear to bring no advantage at this time. Therefore, since the 482 483 model predicts that there is likely some efficacy remaining in F1 and that both S1 and S2 currently provide little comparative advantage, the decision is to continue the therapy 484 until the next imaging time point. 485

486

487 Second follow-up analysis

For any patient in follow-up, the ETB process repeats with each new scan. Volumetric measures for the next follow-up scan were attained and the updated analysis is shown in **Figure 2D**. The tumor has continued to shrink, albeit at a slower rate than during the initial phase. Reanalyzing the data with the model leads to updated predictions for the

TTN, which now ranges from 0 to 1.7 months (from the reanalysis time point). This suggests that the efficacy of F1 is approaching its end. The insets in the figure show the predicted efficacy of the two second-strike options, and as opposed to **Figure 2C**, both now are likely to have a better effect on tumor burden than continuing with F1.

496

497 **Decision support in the ETB**

The ETB is a non-interventional trial, and therefore the decisions of when to switch 498 therapies and what to switch to remain in the hands of the oncologist and the patient. 499 Here, the model analysis and predictions used in the ETB workflow aim to give insight 500 into the temporal dynamics of the patient's specific disease, which can aid in making the 501 above decisions. In the exemplar case above, the model initially suggested continuing 502 503 the first strike, and similarly continuing after the first follow-up imaging point, after which the model began to suggest that a second-strike option should be applied soon. For this 504 patient, an additional treatment option, radiotherapy, arose at the time, and was chosen 505 506 as a second strike. The insight gained regarding the efficacy and expected nadir of the first strike was valuable in making the subsequent treatment decisions for the patient. 507

508

509 **DISCUSSION**

Here we report the first results of the ETB feasibility study, having built a system to capture available clinical tumor dynamics over time and in response to available therapies, to incorporate the remaining conventional therapeutic options, and created a forum and methodology for disciplines with an evolutionary understanding of cancer to discuss ideas and implement them for patients. We also highlight a specific patient to

provide more detail of the process of building a model and using it to guide timing and selection of available therapies in a novel and dynamic manner. We leveraged the existing framework of clinical tumor boards, the well-established best practice care delivery model in oncology, in combination with quantitative analysis^{7,15}. ETB uniquely includes non-clinical disciplines and integrates eco-evolutionary concepts to generate novel treatment strategies and assesses the results of this platform over time.

521

522 To date we have primarily analyzed patients with HNSCC while additional investigations 523 into adolescent and young adult sarcomas, prostate, breast, and lung cancers are ongoing. Successfully expanding to additional disease sites depends on many factors. 524 A key aspect is having the option to change therapies in real time during follow-up. In 525 526 addition, availability of retrospective cohorts to inform model development is critical to their utility. Figure 3 shows how we envision the current incarnation of the ETB in 527 facilitating the integration of evolutionary therapies into standard practice. Early on, the 528 529 ETB serves as a test bed for developing models, understanding the evolutionary dynamics of the disease, and creating potential clinical trials. In later stages, pilot trials 530 531 will be served by a robust framework using highly calibrated mathematical model(s) developed for that trial. If successful, we envision developing disease-specific software 532 modules that will assist the oncologist in decision support during standard of care, 533 534 particularly in practice environments without access to multidisciplinary tumor board. 535 This long-term vision delivers the insights gained from mathematical modeling of 536 evolutionary dynamics into the hands of any interested oncologist for personalized 537 decision support.

538

The ETB invites consideration of evolutionarily enlightened therapy approaches. Our 539 primary focus here has been using multi-strike therapy to effect maximal tumor 540 541 reduction, ideally extinction, while minimizing the effect of tumor resistance to any given agent. Evolutionary theory suggests that it is best to switch therapies either just before 542 or at the nadir of the tumor volume under the current therapy (as opposed to waiting for 543 progression to occur and be observed on imaging) because the nadir is believed to 544 represent the point that the tumor population has effectively evolved resistance to the 545 first-strike therapy. A key tool in this approach is predictive modeling, which can 546 estimate time-to-progression before it occurs. In the best case, multi-strike therapy can 547 effect a cure, but even in the absence of such, the approach has the potential to deliver 548 549 deeper remission, both in terms of tumor volume and PFS.

550

There are several other eco-evolutionary concepts that are already in application or in 551 552 development. One of the more developed is adaptive therapy, which typically exploits the evolutionary costs of resistance such as synthesis, maintenance, and operation of 553 the molecular machinery needed to survive treatment. The benefits of resistance 554 555 exceed costs during therapy. This has best been demonstrated thus far clinically in prostate cancer¹⁶ but also in preclinical models of breast cancer¹⁷. Adaptive therapy is 556 557 predicted to be most effective when there is a competitively dominant sensitive 558 population of cancer cells, typically present in clinical situations that have high response rate but a low cure rate. It also requires a treatment strategy that reliably induces a 559 560 response. With continuous therapy or metronomic therapies that do not consider the

patient's tumor dynamics, competitively subordinate resistant cancer cells come to predominate as they experience competitive release from the absence of the drugsensitive cancer cells¹⁸⁻²⁰. By removing therapy while there is still a high frequency and density of sensitive cells, these sensitive cells effectively compete with and therefore suppress the resistant cancer cells. Adaptive therapy is an important and active area of evolutionary therapy research^{16,17,19,21-32} that can encompass multiple drugs^{31,32} and has already been considered for some ETB patients.

568

We plan to initiate several clinical trials to better examine the ETB approach with 569 570 respect to accuracy, predictability, and outcomes. However, much work remains to be done. First, the models will be improved with more real-world data, and thus increased 571 572 analysis of additional retrospective cohorts in each disease will serve to better constrain the operating parameter ranges we apply in our models. Second, compared to imaging, 573 collecting additional biomarkers such as cfDNA has the potential to provide faster 574 575 turnaround, more frequent and even potentially more accurate information on tumor dynamics, particularly in minimal residual disease states. Third, streamlining the 576 process of clinical annotation, literature searches, biomarker collection, analysis, and 577 prediction will be necessary to apply this labor-intensive workflow on a wider scale, 578 though having performed the process for a given diagnosis provides efficiencies for 579 580 future ETB patients. To this end, we are developing a framework that automates much of the process from start to finish, allowing the ETB team to focus on key discussion 581 points regarding the model predictions and patient assumptions that drive the next 582 583 decision point. Ultimately, we hope to continue to improve the therapeutic paradigm of

- clinical oncology application based on the insight gained from ETB. We anticipate the
- tools generated will inform both sequences and strategies of multi-strike therapy across
- a number of cancers and directly facilitate the likelihood of cancer extinction.

587 **REFERENCES**

- Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. *CA Cancer J Clin* 72, 7-33 (2022). https://doi.org:10.3322/caac.21708
- 591 2 Stankova, K., Brown, J. S., Dalton, W. S. & Gatenby, R. A. Optimizing Cancer Treatment 592 Usina Game Theory: А Review. JAMA Oncol 5. 96-103 (2019). https://doi.org:10.1001/jamaoncol.2018.3395 593
- 3 Gatenby, R. A. & Brown, J. Mutations, evolution and the central role of a self-defined fitness function in the initiation and progression of cancer. *Biochim Biophys Acta* **1867**,
- 596
 162-166 (2017). https://doi.org:10.1016/j.bbcan.2017.03.005
- Gravenmier, C. A., Siddique, M. & Gatenby, R. A. Adaptation to Stochastic Temporal
 Variations in Intratumoral Blood Flow: The Warburg Effect as a Bet Hedging Strategy. *Bull Math Biol* 80, 954-970 (2018). <u>https://doi.org:10.1007/s11538-017-0261-x</u>
- Gatenby, R. A., Zhang, J. & Brown, J. S. First Strike-Second Strike Strategies in
 Metastatic Cancer: Lessons from the Evolutionary Dynamics of Extinction. *Cancer Res* (2019). <u>https://doi.org:10.1158/0008-5472.CAN-19-0807</u>
- 603 6 Gatenby, R. A., Artzy-Randrup, Y., Epstein, T., Reed, D. R. & Brown, J. S. Eradicating
 604 metastatic cancer and the eco-evolutionary dynamics of Anthropocene extinctions.
 605 *Cancer Res* (2019). https://doi.org:10.1158/0008-5472.CAN-19-1941
- Kim, E., Rebecca, V. W., Smalley, K. S. & Anderson, A. R. Phase i trials in melanoma: A
 framework to translate preclinical findings to the clinic. *Eur J Cancer* 67, 213-222 (2016).
 https://doi.org:10.1016/j.ejca.2016.07.024

- 609 8 Chung, C. H. et al. Concurrent Cetuximab and Nivolumab as a Second-Line or beyond 610 Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell I/II 611 Carcinoma: Results of Phase Study. Cancers 13 (2021). https://doi.org:10.3390/cancers13051180 612
- 613 9 Chung, C. H. *et al.* Phase II multi-institutional clinical trial result of concurrent cetuximab
 614 and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma.
 615 *Clin Cancer Res* (2022). <u>https://doi.org:10.1158/1078-0432.CCR-21-3849</u>
- 616 10 Brady, R. & Enderling, H. Mathematical Models of Cancer: When to Predict Novel Therapies, 81. 3722-3731 617 and When Not to. Bull Math Biol (2019). 618 https://doi.org:10.1007/s11538-019-00640-x
- Claret, L. *et al.* Model-based prediction of phase III overall survival in colorectal cancer
 on the basis of phase II tumor dynamics. *J Clin Oncol* 27, 4103-4108 (2009).
 https://doi.org:10.1200/JCO.2008.21.0807
- Claret, L. *et al.* Evaluation of tumor-size response metrics to predict overall survival in
 Western and Chinese patients with first-line metastatic colorectal cancer. *J Clin Oncol*31, 2110-2114 (2013). <u>https://doi.org:10.1200/JCO.2012.45.0973</u>
- Glazar, D. J. *et al.* Tumor Volume Dynamics as an Early Biomarker for Patient-Specific
 Evolution of Resistance and Progression in Recurrent High-Grade Glioma. *J Clin Med* 9
 (2020). https://doi.org:10.3390/jcm9072019
- Glazar, D. J. et al. Early response dynamics predict treatment failure in patients with 628 14 recurrent and/or metastatic head and neck squamous cell carcinoma treated with 629 630 cetuximab and nivolumab. Oral Oncol **127**, 105787 (2022). https://doi.org:10.1016/j.oraloncology.2022.105787 631
 - 29

- Pasetto, S., Gatenby, R. A. & Enderling, H. Bayesian Framework to Augment Tumor 632 15 633 Board Decision Making. JCO Clin Cancer Inform 5, 508-517 (2021).634 https://doi.org:10.1200/CCI.20.00085
- ⁶³⁵ 16 Zhang, J., Cunningham, J. J., Brown, J. S. & Gatenby, R. A. Integrating evolutionary
- 636 dynamics into treatment of metastatic castrate-resistant prostate cancer. *Nat Commun* **8**,
- 637 1816 (2017). <u>https://doi.org:10.1038/s41467-017-01968-5</u>
- Enriquez-Navas, P. M. *et al.* Exploiting evolutionary principles to prolong tumor control in
 preclinical models of breast cancer. *Sci Transl Med* 8, 327ra324 (2016).
 https://doi.org:10.1126/scitranslmed.aad7842
- 641 18 Gillies, R. J., Flowers, C. I., Drukteinis, J. S. & Gatenby, R. A. A unifying theory of
 642 carcinogenesis, and why targeted therapy doesn't work. *Eur J Radiol* 81 Suppl 1, S48643 50 (2012). <u>https://doi.org:10.1016/S0720-048X(12)70018-9</u>
- Gatenby, R. A., Silva, A. S., Gillies, R. J. & Frieden, B. R. Adaptive therapy. *Cancer Res*645 69, 4894-4903 (2009). https://doi.org:10.1158/0008-5472.CAN-08-3658
- Gatenby, R. A., Brown, J. & Vincent, T. Lessons from applied ecology: cancer control
 using an evolutionary double bind. *Cancer Res* 69, 7499-7502 (2009).
 https://doi.org:10.1158/0008-5472.CAN-09-1354
- Brady-Nicholls, R. *et al.* Prostate-specific antigen dynamics predict individual responses
 to intermittent androgen deprivation. *Nat Commun* **11**, 1750 (2020).
 https://doi.org:10.1038/s41467-020-15424-4

- Brady-Nicholls, R. et al. Predicting patient-specific response to adaptive therapy in
- 653 metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics.
- 654 *Neoplasia* **23**, 851-858 (2021). <u>https://doi.org:10.1016/j.neo.2021.06.013</u>
- Cunningham, J. *et al.* Optimal control to reach eco-evolutionary stability in metastatic
 castrate-resistant prostate cancer. *PLoS One* **15**, e0243386 (2020).
 <u>https://doi.org:10.1371/journal.pone.0243386</u>
- Gallaher, J. A., Enriquez-Navas, P. M., Luddy, K. A., Gatenby, R. A. & Anderson, A. R.
- A. Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in
- 660 Continuous and Adaptive Cancer Therapies. Cancer Res 78, 2127-2139 (2018).
- 661 https://doi.org:10.1158/0008-5472.CAN-17-2649
- Kim, E., Brown, J. S., Eroglu, Z. & Anderson, A. R. A. Understanding the potential
 benefits of adaptive therapy for metastatic melanoma. *bioRxiv*, 2020.2010.2016.343269
 (2020). <u>https://doi.org:10.1101/2020.10.16.343269</u>
- Kim, E., Brown, J. S., Eroglu, Z. & Anderson, A. R. A. Adaptive Therapy for Metastatic
- Melanoma: Predictions from Patient Calibrated Mathematical Models. *Cancers (Basel)*13 (2021). https://doi.org:10.3390/cancers13040823
- 668 27 Mason, N. T. *et al.* Budget Impact of Adaptive Abiraterone Therapy for Castration-669 Resistant Prostate Cancer. *Am Health Drug Benefits* **14**, 15-20 (2021).
- 67028Strobl, M. A. R. *et al.* Spatial structure impacts adaptive therapy by shaping intra-tumoral671competition.*bioRxiv*,2020.2011.2003.365163(2021).
- 672 <u>https://doi.org:10.1101/2020.11.03.365163</u>

673	29	Strobl, M. A. R. et al. Turnover Modulates the Need for a Cost of Resistance in Adaptive
674		Therapy. Cancer Res 81, 1135-1147 (2021). <u>https://doi.org:10.1158/0008-5472.CAN-20-</u>
675		<u>0806</u>

- West, J., Ma, Y. & Newton, P. K. Capitalizing on competition: An evolutionary model of
- 677 competitive release in metastatic castration resistant prostate cancer treatment. *J Theor*
- 678 *Biol* **455**, 249-260 (2018). <u>https://doi.org:10.1016/j.jtbi.2018.07.028</u>
- West, J. *et al.* Towards Multidrug Adaptive Therapy. *Cancer Res* 80, 1578-1589 (2020).
 https://doi.org:10.1158/0008-5472.CAN-19-2669
- West, J. B. *et al.* Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate
 Cancer: An Evolution-Based Strategy. *Clin Cancer Res* (2019).
 https://doi.org:10.1158/1078-0432.CCR-19-0006

Table 1. Patient characteristics

Variables		ETB N=15	HNSCC Retrospective Cohort N=26
Age	Median	59	64
Gender	Male	12 (80%)	23 (88%)
	Female	3 (20%)	3 (12%_
Race	White	13 (87%)	25 (96%)
	Black	1 (7%)	0
	Other	1 (7%)	1 (4%)
ECOG PS	0	8 (53%)	7 (27%)
	1	6 (40%)	19 (73%)
	2	1 (7%)	0
Smoking History	Yes	6 (40%)	17 (65%)
	No	9	9
Disease Site	HNSCC	6 (40%)	26 (100%)
	Sarcoma	7 (47%)	0
	Lung	1 (7%)	0
	Prostate	1 (7%)	0
Prior line of therapy for R/M cancers	0	0 (0%)	6 (23%)
	1	6 (40%)	13 (50%)
	2	6 (40%)	5 (19%)
	3	0 (0%)	2 (8%)
	4	3 (20%)	0 (0%)

ETB: evolutionary tumor board

HNSCC: head and neck squamous cell carcinoma

ECOG PS: Eastern Cooperative Oncology Group Performance Status R/M: recurrent and/or metastatic

Table 2. Retrospective head and neck squamous cell carcinoma cohort characteristics (N=26)

Variables	Mean	Min/Max Range
Number of lesions per patient	2.61	1 to 5
Number of scans per lesion	4.16	2 to 13
Parameter fits for γ (per day)	0.027	0.008 to 0.061
Parameter fits for δ / γ for cetuximab + nivolumab	2.2	1.1 to 3.7
Parameter fits for <i>r</i> (per day) for cetuximab + nivolumab	0.0076	0.002 to 0.013

ETB ID	Clinical Presentation at ETB	ETB Recommendation	Implemented by physician
ETB-001	Metastatic Ewing sarcoma with prolonged stable disease and unresectable disease burden	Three strike strategy: Short course doxorubicin. Radiation therapy to lung metastasis (whole lung vs stereotactic depending on response) with a systemic therapy backbone (tyrosine kinase inhibitor or vincristine) and then return to vincristine and irinotecan cycled with a tyrosine kinase inhibitor (regorafenib).	doxorubicin + dexrazoxane + cyclophosphamide
ETB-002	Metastatic alveolar rhabdomyosarcoma entering second complete response	Radiation therapy to the forearm lesion, chemotherapy, anti-angiogenesis inhibitor (rotating 90-day cycles)	pazopanib + radiation therapy
ETB-003	Metastatic HPV positive poorly differentiated carcinoma of base of tongue who presented while on nivolumab + cetuximab clinical trial	Maintain combination of nivolumab + cetuximab treatment for at least 90 days from initiation, but not greater than 120 days based on the model. Then switch to a second strike with an available chemotherapy with nivolumab. Nivolumab will be continued as maintenance. Maintain second strike for 90-120 days and then consider switching the chemotherapy again based on the current estimated tumor proliferation rate.	continued nivolumab + cetuximab
ETB-004	Metastatic HPV positive base of tongue squamous cell carcinoma presented with progressive disease on the second line palliative systemic therapy	Discontinue current therapy and initiate concurrent cisplatin or carboplatin + paclitaxel with radiation as a second strike to achieve durable locoregional control. Possibility of radiating the sternal metastasis for palliation will be assessed by the radiation oncology team. As soon as the patient recovers from the radiation induced toxicities, resume an appropriate systemic therapy again to control the lung metastasis.	cisplatin + radiation therapy
ETB-005	Widespread metastatic bone and lung osteosarcoma in first 6 months of MAP	No: Recommendation N/A due to death of the patient after enrolling to the study but before the ETB presentation.	N/A
ETB-006	p16-positive right tonsil squamous cell carcinoma progressed on the first line of palliative systemic therapy	Discontinue the first line carboplatin + paclitaxel. Switch to cisplatin + 5- fluorouracil + pembrolizumab as a second strike. Continue pembrolizumab as maintenance. Introduce second strike of a dose-reduced cisplatin + 5- fluorouracil because the patient had problems with neutropenia given the prior regimen. Alternately, cisplatin + 5- fluorouracil can be given as a full dose by adding a growth factor to prevent prolonged neutropenia.	cisplatin + 5- fluorouracil + pembrolizumab

Table 3. Evolutionary Tumor Board (ETB) Recommendations

ETB-007	Gleason 8 Prostate cancer with widespread bone metastases	Begin an adaptive therapy using enzalutamide + relugolix. Use 50% PSA decline as threshold for stopping therapy and increase of PSA to resume. Follow patient closely to calibrate modeling and potentially alter the recommendation of start-stop algorithm	enzalutamide + relugolix
ETB-008	Osteosarcoma with metastasess in lung with good response	No: Recommendation N/A due to insufficient historical data/analysis at the time of ETB to predict response to additional therapy options.	N/A
ETB-009	Widely metastatic embryonal rhabdomyosarcoma with LN, bone and lung metastases newly diagnosed	If the first strike results in disease progression or stable disease, then change to doxorubicin-based therapy. If partial response after the first evaluation, continue vincristine + Adriamycin + cyclophosphamide (VAC) and determine intensify or de-intensify the regimen. Second strike: vincristine + irinotecan after complete response between 12-42 weeks of VAC.	VAC → vincristine + irinotecan
ETB010	Metastatic HPV positive base of tongue squamous cell carcinoma	Await the next follow-up scan to refine the model predictions and decide when to switch to next line of therapy.	pembrolizumab
ETB-011	Metastatic oropharynx (posterior pharyngeal wall) squamous cell carcinoma	Switch to cetuximab + pembrolizumab instead of administering the final cycle of cisplatin + 5-fluorouracil + pembrolizumab based on evidence of progression. Expect cetuximab to provide 2 to 7 months of efficacy. Nadir of efficacy expected in 1 to 4 months, so close attention to upcoming scans should be given to anticipate the next switch of therapy.	cetuximab + pembrolizumab
ETB-012	Adenocarcinoma with metastasis to liver	No: Recommendation N/A due to the patient taken off the study at physician's discretion before the ETB presentation.	N/A
ETB-013	Synchronous floor of mouth (cT1N0M0) and left base of tongue (cT2N0M0) squamous cell carcinoma, both p16 negative.	Next scan will be critical for predicting nadir of response. Scan delayed by insurance, so results pending for now. Consider starting the palliative radiation therapy sooner after getting the next scan.	palliative radiation therapy
ETB-014	Recurrent esthesioneuroblastoma	No: Recommendation N/A due to the lack of measurable lesions and delay in patient presentation.	N/A
ETB-015	Bone metastatic Ewing sarcoma with initial response to chemotherapy	Continue vincristine + doxorubicin + cyclophosphamide /ifosfamide + etoposide (VDC/IE). Patient is in the 2nd strike window.	continue VDC/IE

Figure 1A.



Figure 1B.

ETB-003



Figure 1C.



Figure 1. A: Schematic diagram of the Evolutionary Tumor Board clinical workflow. **B:** An example of tumor volumetric data visualization in context of the clinical data. **C:** An

example of tumor volumetric data visualization based on a mathematical model using a system of ordinary differential equations in context of the treatment data.

Figure 2A.







Figure 2C.



Figure 2D.



Figure 2. A: Overview of the ETB mathematical modeling using the tumor <u>G</u>rowth, tumor <u>D</u>eath, evolution of drug <u>R</u>esistance, and drug re-<u>S</u>ensitization (GDRS) model and decision support workflow. **B:** The initial analysis of the patient. The bottom section of the figure shows the treatments received over time. The top section of plot shows the volumes of each lesion (different colors for each lesion) on a log_{10} scale, over time, with clinical data from imaging represented by dots, and model fits represented by lines. Here, the model fit for the largest primary lesion is plotted (purple), as well as for the largest lung metastasis (teal). The 'x' markers represent scans with no detectable volume for that lesion (below the detection threshold for the instrument, represented by the dashed line).

The vertical solid line represents the time when the first ETB for the patient occurred, and the vertical dashed line indicated the next expected date of imaging. The model is used to create a cone of outcomes (shaded areas). The wide cone represents the range of outcomes seen in retrospective patients; the inner shaded cones represent the average retrospective patient, and the patient-specific predictions for the current patient.

C: First follow-up analysis by the ETB (solid vertical line). This occurs shortly after the patient has received their first imaging scan on the current therapy. The new prediction cone is significantly narrowed, given the additional data point. Inset A shows the prediction cone for immediately switching therapy to carboplatin and paclitaxel (purple cone), and inset B shows the predictions if the patient were immediately switched to cisplatin and 5-FU. **D**: Second follow-up analysis by the ETB (solid vertical line). This occurs shortly after the patient's second scan on current therapy. As in **Figure 2C**, the prediction cones for the two options for second strikes are shown in the insets.



Figure 3. Three phases of the ETB. The development phase (red) is where models and evolutionary therapy approaches are developed for each specific disease setting based on available biomarkers. Retrospective cohorts are curated and analyzed. The second phase (blue) brings the ETB approach to disease-specific clinical trials, using a Phase 'i' virtual trial approach for patient decision support. Models and biomarker collection are refined, and patient cohorts are expanded. In phase three (green), validated approaches are deployed for broad clinical use, via custom software developed for the specific disease. This system can be self-improving with each patient that is seen via the approach, contributing valuable data and outcomes to the retrospective cohort for a given disease.